Findings support central nervous system penetration and functional brain activity differentiated from the classic psychedelic DMT
Results support use of qEEG as a potential pharmacodynamic biomarker in first-in-human
Completed IND-enabling in vitro Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) studies, demonstrating favorable and efficient oral absorption and systemic bioavailability
Results further derisk
Allowed claims are expected to cover novel methylone-inspired neuroplastogenic compounds for potential treatment of post-traumatic stress disorder (PTSD) and other psychiatric disorders
Enveric Biosciences
Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders,
EB-003 Development Highlights:
Continued advancing IND-enabling studies supporting the planned submission of an Investigational New Drug (IND) application for EB-003 and expected initiation of Phase 1 clinical
GloSensor™ assay findings align with previously reported BRET assay data as EB-003 advances toward planned Phase 1 clinical development
Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"),
FDA guidance highlights clinical and delivery challenges associated with hallucinogenic compounds, supporting the potential advantages of Enveric’s EB-003 approach
Enveric Biosciences (NASDAQ:ENVB) ("Enveric"
Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders,
Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced
Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced
Studies are designed to evaluate the potential for the compound to interact with DNA and cause genetic mutations, a critical measure of safety required for IND submission
Enveric Biosciences (NASDAQ:ENVB) ("Enveric"
Analysis showed no photoreactive potential for EB-003, further derisking its continued development for the treatment of neuropsychiatric disorders including depression, anxiety and PTSD.
Phototoxicity testing is a
Product Development Highlights:
Continued advancement of lead candidate EB-003 with IND-enabling studies progressing toward planned first-in-human clinical trial
Reported additional preclinical data for EB-003
Claims to methods for treating a psychiatric disorder using novel pharmaceutical drug formulations encompass an EVM301 Series of drug candidates of carboxylated psilocybin derivatives, targeting various
Previously reported results support continued development of EB-003 for PTSD and other neuropsychiatric conditions
Recent U.S. Executive Order supporting psychedelic-inspired therapies highlights growing focus on PTSD
